| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 12,134 |
| Amortization of operating lease right-of-use assets | 1,080 |
| Prepaid expenses and other current assets | -316 |
| Other non-current assets | -5,311 |
| Operating lease liabilities | -6,447 |
| Accounts payable | 6,533 |
| Impairment of long-lived assets | 10,197 |
| Depreciation | 712 |
| Accretion on investments in marketable securities | 1,478 |
| Accrued restructuring costs | 10,646 |
| Accrued expenses and other current liabilities | -8,590 |
| Accrued clinical and research and development expenses | -11,721 |
| Acquired in-process research and development | 665 |
| Net cash used in operating activities | -115,077 |
| Proceeds from sales and maturities of marketable securities | 241,756 |
| Purchase of property and equipment | 481 |
| Purchases of marketable securities | 81,687 |
| Purchase of in-process research and development | 1,188 |
| Net cash provided by (used in) investing activities | 158,400 |
| Proceeds from exercise of stock options | 43 |
| Net cash provided by financing activities | 43 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 43,366 |
CARGO Therapeutics, Inc. (CRGX)
CARGO Therapeutics, Inc. (CRGX)